The intention of this study is to provide a detailed and thorough analysis of the present and future global market for cancer therapeutics. This report analyzes in detail the markets for colorectal cancer, prostate cancer, lung cancer, breast cancer, leukemia and non-Hodgkin’s lymphoma.

In a market currently valued around US$42 billion, cancer chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years according to Spectra’s expert cancer report.

The stakes are high in the global oncology market, currently estimated at US$42 billion. Hundreds of novel and next-generation anticancer products are in research and development; however, not all are destined for market success and an estimated 37% or more key preclinical candidates may fail due to poor clinical performance despite increasing investment.

This report provides an overview of the emerging market for cancer vaccines and measures their potential impact on a number of cancer markets. Vaccine product candidates are discussed within the context of the disease areas they are attempting to penetrate and include: melanoma, prostate cancer, colorectal cancer, lung cancer, breast cancer, and pancreatic cancer.